However, the tumor inhibitory effect of this vaccine was significantly improved when administrated with PD-1 antibody, since PAS increased the number of CD8 + T cells and decreased the number of M2-type macrophages, making the TME more sensitive to other treatments. The gene discussed is PDCD1; the disease is neoplasm.